Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
.webp)
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
You can also access detailed information by clicking Login in the website header.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
USA
Regulatory Approval:
N/A
Your Trustedworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Opdualag (nivolumab and relatlimab-rmbw) is a fixed-dose combination immunotherapy approved by the FDA for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma.
Opdualag combines nivolumab, a PD-1 inhibitor, with relatlimab, the first FDA-approved LAG-3 inhibitor. Together, these two checkpoint inhibitors block two distinct immune checkpoint pathways that cancer cells use to evade the immune system, providing a dual mechanism of immune activation against melanoma.
Opdualag is intended for patients with unresectable or metastatic melanoma who have not previously been treated, offering a combination immunotherapy approach for this advanced skin cancer.
The recommended dose of Opdualag is 480 mg nivolumab and 160 mg relatlimab administered as an intravenous infusion over 30 minutes, every 4 weeks, until disease progression or unacceptable toxicity.
Opdualag does not carry a formal FDA boxed warning. However, patients and prescribers should be aware of the following important safety information.
Opdualag can cause severe or fatal immune-mediated adverse reactions affecting any organ system, including pneumonitis, colitis, hepatitis, endocrinopathies, and skin reactions. Close monitoring and management with corticosteroids or treatment interruption may be required.
Fatal and other serious complications can occur in patients who undergo allogeneic hematopoietic stem cell transplantation before or after Opdualag treatment.
Infusion-related reactions have been reported. Treatment should be interrupted, slowed, or discontinued based on severity.
Opdualag may cause fetal harm. Effective contraception should be used during treatment and for a period after the final dose, as advised by the treating physician.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Opdualag is manufactured and marketed by Bristol-Myers Squibb. It is sourced through authorized distribution channels for patients seeking named-patient import into India. Opdualag's nivolumab component is also available separately as Opdivo.
Patients typically need a valid prescription from a treating oncologist confirming a diagnosis of unresectable or metastatic melanoma. NPP's regulatory team assists in preparing and verifying the documentation needed for a compliant import.
As an FDA-approved dual-checkpoint immunotherapy for melanoma, Opdualag is sourced through authorized channels and imported under GDP-compliant, cold-chain logistics to preserve product quality throughout transit.
NPP sources Opdualag directly from authorized pharmaceutical distributors to ensure product authenticity and full traceability. Every shipment is handled under Good Distribution Practice (GDP) conditions from origin to the patient's doorstep.
Opdualag requires refrigerated storage at 2°C to 8°C, protected from light. NPP maintains a continuous, monitored cold chain throughout transit.
Once documentation and regulatory approvals are in place, delivery timelines are communicated transparently at the time of quotation, accounting for import clearance and last-mile cold-chain logistics to the patient's city.
Patients across India can access Opdualag through NPP's regulated import pathway, with oncology specialists in major cities supporting the treatment process.
Leading hospitals in Mumbai support oncology care coordination and documentation for Opdualag access.
Delhi's major hospitals assist patients with prescription support and documentation for Opdualag.
Bangalore's specialist network offers access coordination for eligible melanoma patients seeking Opdualag.
Chennai-based oncology specialists coordinate Opdualag access alongside comprehensive melanoma care.
Hyderabad's care institutions support patients pursuing Opdualag therapy.
Kolkata's specialist centers help coordinate documentation and treatment access for Opdualag.
Pune-based specialists assist with prescription support and Opdualag treatment planning.
Ahmedabad's specialty hospitals support the import and treatment process for Opdualag.
Kochi's specialist units assist patients with the documentation needed for Opdualag access.
Chandigarh's care centers support Opdualag treatment coordination for patients from North India.
Jaipur's specialists help patients navigate the Opdualag access process.
Lucknow-based centers assist patients pursuing Opdualag therapy.
Bhubaneswar's institutions support access to Opdualag for eligible patients.
Guwahati's specialists help coordinate Opdualag access for patients across the Northeast.
Patients in other cities across India can also access Opdualag through NPP's nationwide coordination network.
Written By: Nitin Goswami, Senior Medical Content Writer
Last Updated: 15 September 2026
Sources: FDA
Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Last Updated: 15 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
